menu
    • menu

    Company profile for OBI Pharma

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    OBI Pharma, Inc. is a Taiwan based bio-pharma company founded in 2002. Our mission is to improve health and the quality of life through innovative cancer therapeutics. We seek to develop and license novel therapeutic agents for unmet medical needs against cancer by targeting the Globo Series antigens (Globo H, SSEA-4), the AKR1C3 enzyme, and other promising targets. Our leading compound is Adagloxad simolenin, a late-stage nov...
    OBI Pharma, Inc. is a Taiwan based bio-pharma company founded in 2002. Our mission is to improve health and the quality of life through innovative cancer therapeutics. We seek to develop and license novel therapeutic agents for unmet medical needs against cancer by targeting the Globo Series antigens (Globo H, SSEA-4), the AKR1C3 enzyme, and other promising targets. Our leading compound is Adagloxad simolenin, a late-stage novel active immuno-oncology (IO) Globo Series-based therapeutic vaccine for the treatment of epithelial cancers, such as breast, ovarian, lung, prostate, colon, gastric, and pancreatic cancer.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    OBI PharmaTaiwan Flag
    Country
    Country
    Taiwan
    Address
    Address
    7F, No. 369, Zhongxiao E Rd Nangang District, Taipei City, 115
    Telephone
    Telephone
    +886-2-2786-6589
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.obipharma.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/obi-pharma-inc
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    US FDA Grants Orphan Drug Designation To OBI-902
    US FDA Grants Orphan Drug Designation To OBI-902

    17 Nov 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-11-17/obi-902-has-been-granted-by-us-fda-for-orphan-drug-designation-for-the-treatment-of-cholangiocarcino

    PHARMIWEB
    17 Nov 2025
    Share Share
    OBI Pharma Begins Phase 1/2 Study for OBI-902 in Advanced Tumors
    OBI Pharma Begins Phase 1/2 Study for OBI-902 in Advanced Tumors

    02 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/02/3142393/0/en/OBI-Pharma-Announces-Phase-1-2-Study-Initiation-for-OBI-902-a-TROP2-Targeted-Antibody-Drug-Conjugate-Therapy-ADC-in-Advanced-Solid-Tumors.html

    GLOBENEWSWIRE
    02 Sep 2025
    Share Share
    OBI Pharma, TegMine Partner On ADCs Using GlycOBI & TegMiner Tech
    OBI Pharma, TegMine Partner On ADCs Using GlycOBI & TegMiner Tech

    06 Jun 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/06/06/3094901/0/en/OBI-Pharma-Enters-ADC-Collaboration-with-TegMine-Therapeutics-utilizing-GlycOBI-and-TegMiner-Enabling-Technologies.html

    GLOBENEWSWIRE
    06 Jun 2025
    Share Share
    OBI Pharma's OBI-902 Phase 1/2 Study IND Cleared by FDA
    OBI Pharma's OBI-902 Phase 1/2 Study IND Cleared by FDA

    30 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/05/01/3072034/0/en/OBI-Pharma-Announces-U-S-FDA-Clearance-of-IND-Application-for-a-Phase-1-2-Study-of-OBI-902-a-Trop-2-Targeting-ADC.html

    GLOBENEWSWIRE
    30 Apr 2025
    Share Share
    OBI Pharma presents ADC posters at AACR 2025 Annual Meeting
    OBI Pharma presents ADC posters at AACR 2025 Annual Meeting

    22 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/23/3066042/0/en/OBI-Pharma-Announces-Poster-Presentations-at-the-AACR-2025-Annual-Meeting-for-OBI-992-and-OBI-902-Antibody-Drug-Conjugates-ADCs-GlycOBI-and-ThiOBI-ADC-enabling-technologies-the-OBI.html

    GLOBENEWSWIRE
    22 Apr 2025
    Share Share
    OBI Pharma Wins ‘Most Promising ADC Clinical Candidate’ In Taiwan
    OBI Pharma Wins ‘Most Promising ADC Clinical Candidate’ In Taiwan

    12 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2025/03/12/3041279/0/en/OBI-Pharma-Receives-Most-Promising-ADC-Clinical-Candidate-in-Taiwan-Award.html

    GLOBENEWSWIRE
    12 Mar 2025
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search